Skip to content

Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor

Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043336
Enrollment
Unknown
Registered
2021-02-11
Start date
2020-05-01
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy donor

Interventions

Case series:Nil

Sponsors

Taizhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 18-40 years, no donation reaction in the past; 2. Weight: male >= 50 kg, female >= 45 kg, and 18.5 kg/m2 = 50/min, with regular rhythm; 5. Temperature: 36.3-37.2 degrees C (oral temperature); 6. Generally in good condition: no damage to important organs such as heart, lung, liver and kidney; no severe or uncontrolled infection; no history of severe mental disorders.

Exclusion criteria

Exclusion criteria: 1. Valetudinarian, with frequent dizziness, giddiness, tinnitus, hemophobia, fear of needles, faint, and Meniere's disease; 2. Sexually transmitted diseases (STDs), leprosy, AIDS, and HIV-1, HIV-2, CMV, EBV antibody positive; 3. History of liver diseases, HBsAg positive and HCV antibody positive. 1 year after the clinical cure of hepatitis A, normal ALT test results at 1 month interval for 3 consecutive times; 4. Relapsed allergic diseases, urticaria, bronchial asthma and drug allergies (Donors with simple urticaria who are not in acute attack are eligible to donate PBMC); 5. Pulmonary tuberculosis, renal tuberculosis, lymph node tuberculosis and bone tuberculosis; 6. Urinary system diseases (e.g. acute and chronic nephritis, chronic urinary system infection, nephrotic syndrome, acute and chronic renal insufficiency, etc.); 7. Various hematological diseases (including anemia, leukemia, polycythemia vera and various hemorrhagic and coagulative diseases); 8. Endocrine diseases or metabolic disorders (e.g. hyperthyroidism, acromegaly, diabetes, insipidus, diabetes mellitus, etc.); 9. Organic nervous system diseases or psychoses (e.g. encephalitis, sequelae of brain trauma, epilepsy, schizophrenia, hysteria, severe neurasthenia, etc.); 10. Parasitic diseases and endemic diseases (e.g. kala-azar, schistosomiasis, filariasis, hookworm disease, taeniasis, paragonimiasis, Keshan disease, Kaschin-Beck disease, etc.); 11. Malignancies and benign tumors affecting health; 12. Undergone resection of stomach, kidney, gallbladder, spleen, lung and other important organs; 13. Exposure to harmful substances or radioactive substances (except for clinical radiology); 14. High-risk groups susceptible to HIV infection, such as drug users, homosexuals and people with multiple sexual partners; 15. Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt disease (vCJD), family history, and treatment with human and animal pituitary-derived substances (e.g. growth hormone, gonadotropin, thyrotropin, etc.). Organ transplantation recipients (including cornea, bone marrow, dura mater) may be exposed to bovine spongiform encephalopathy (BSE) and vCJD; 16. Other diseases or conditions in which donors are ineligible to donate PBMC in the opinion of physicians.

Design outcomes

Primary

MeasureTime frame
Safety evaluation;

Countries

China

Contacts

Public ContactJun Ye
m13625171902@163.com+86 13625171902

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026